| Prev Close | 387.80 |
| Open | 384.17 |
| Day Low/High | 377.09 / 387.19 |
| 52 Wk Low/High | 281.89 / 437.90 |
| Volume | 773.87K |
| Avg Volume | 678.10K |
| Exchange | NASDAQ |
| Shares Outstanding | 106.14M |
| Market Cap | 42.12B |
| EPS | 11.30 |
| P/E Ratio | 28.25 |
| Div & Yield | N.A. (N.A) |
-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
Among 13 Alliance presentations, a late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response
- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
- ESMO data demonstrate breadth of joint Regeneron and Sanofi immuno-oncology development program
Straying from these names could land you in quicksand as the 4th quarter begins.
* Libtayo is the third anti-PD-1 approved in the U.S.
Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.
Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.
* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy
Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.
TARRYTOWN, N.Y.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc.
It is all about perception, and here are strong names to pick up on market weakness.
bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc.
An updated strategy for the high-flying REGN.
Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.
